Table 3.
Association of CDKN2A loss by fluorescence in situ hybridization with overall survival stratified by histologic subtype, pathologic diagnosis, and molecular subtypes using Cox proportional hazards models in glioma patients from the UCSF Adult Glioma Study
| CDKN2A intact | CDKN2A deleted | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | N deceased |
Mean overall survival (years) |
Median overall survival (years) |
N | N deceased |
Mean overall survival (years) |
Median overall survival (years) |
HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Unadjusted | Adjusted for age and sex | |||||||||||||
| All cases* | 159 | 56 | 10.3 | 11.8 | 94 | 42 | 8.8 | 7.2 | 1.7 | 1.1–2.5 | 0.01a | 1.6 | 1.0–2.4 | 0.03 |
| Astrocytoma* | 56 | 23 | 8.7 | 9.5 | 52 | 31 | 5.5 | 4.4 | 2.6 | 1.5–4.6 | 0.0008a | 2.0 | 1.1–3.5 | 0.02 |
| Oligodendroglioma* | 73 | 20 | 11.1 | 15.4 | 19 | 4 | 7.0 | 0.7 | 0.2–1.7 | 0.4 | 0.7 | 0.2–2.00 | 0.5 | |
| Oligoastrocytoma* | 30 | 13 | 9.8 | 10.6 | 23 | 7 | 11.5 | 17.2 | 0.9 | 0.3–2.2 | 0.7 | 0.8 | 0.3–2.4 | 0.7 |
| A-II* | 26 | 9 | 10.2 | 12.8 | 21 | 9 | 6.6 | 6.4 | 3.9 | 1.4–11.2 | 0.01a | 2.7 | 0.8–8.8 | 0.1 |
| A-III* | 30 | 14 | 5.0 | 6.9 | 31 | 22 | 4.7 | 3.3 | 2.1 | 1.1–4.2 | 0.03a | 1.8 | 0.8–3.6 | 0.1 |
| O-II* | 57 | 14 | 9.4 | 11.8 | 17 | 2 | 7.6 | NA | 0.4 | 0.07–1.6 | 0.3 | 0.4 | 0.07–1.5 | 0.2 |
| O-III* | 16 | 6 | 11.2 | 15.4 | 6 | 2 | 1.9 | NA | 1.4 | 0.2–6.6 | 0.7 | 1.6 | 0.2–9.9 | 0.6 |
| OA-II* | 25 | 12 | 9.6 | 10.6 | 15 | 5 | 12.3 | 17.2 | 0.7 | 0.2–2.0 | 0.5 | 1.0 | 0.3–3.1 | 0.9 |
| OA-III* | 5 | 1 | 1.0 | NA | 4 | 2 | 3.4 | 3.7 | 2.8 | 0.3–60.0 | 0.4 | 0.2 | 0.0004–21.2 | 0.6 |
| IDH/TP53 mutated, ATRX lost | 21 | 10 | 10.2 | 12.9 | 21 | 14 | 6.4 | 4.8 | 3.3 | 1.4–8.8 | 0.008a | 3.4 | 1.4–8.4 | 0.008a |
| IDH/TP53 mutated | 28 | 12 | 10.6 | 12.8 | 22 | 15 | 6.3 | 4.8 | 4.3 | 1.8–10.1 | 0.001a | 4.4 | 1.8–10.3 | 0.0008a |
| IDH mutated, ATRX lost | 49 | 19 | 9.6 | 9.2 | 39 | 18 | 8.7 | 7.8 | 1.6 | 0.8–3.0 | 0.2 | 1.6 | 0.8–3.0 | 0.2 |
| IDH mutated, 1p19q codeleted** | 56 | 16 | 9.2 | 10.6 | 16 | 0 | NA | NA | NA | NA | NA | NA | NA | NA |
HR, Hazard ratio; CI, Confidence interval; NA, Median survival is not available due to lack of events.
*
Hazard ratios for histologic groups and pathologic diagnosis were adjusted for IDH mutation status in addition to age and sex.
**
These tumors were also ATRX intact.
A-II, Diffuse astrocytoma; A-III, Anaplastic astrocytoma; O-II, Oligodendroglioma, O-III, Anaplastic oligodendroglioma, OA-II, Oligoastrocytoma; OA-III, Anaplastic oligoastrocytoma.
a
statistical significance at the 0.05 level.